The figure shows the general structure of this class of molecules. A-582941 enhanced cognitive performance in behavioral assays including the monkey delayed matching-to-sample, rat social recognition, and mouse inhibitory avoidance models that capture domains of working memory, short-term recognition memory, and long-term memory consolidation, respectively. Their results demonstrate that alpha-7 nAChR agonism can lead to broad-spectrum efficacy in animal models at doses that enhance ERK1/2 (extracellular-signal regulated kinase) and CREB (cAMP response element-binding protein) phosphorylation/activation and may represent a mechanism that offers potential to improve cognitive deficits associated with neurodegenerative and psychiatric diseases, such as Alzheimer's disease and schizophrenia.
Wednesday, October 10, 2007
An acetylcholine receptor agonist improves cognition
The alpha-7 nicotinic acetylcholine receptor (nAChR) plays an important role in cognitive processes and may represent a drug target for treating cognitive deficits in neurodegenerative and psychiatric disorders. Bitner et al. study the effects of a particular AChR enhancer, or agonist, whose simple name is A-582941.
The figure shows the general structure of this class of molecules. A-582941 enhanced cognitive performance in behavioral assays including the monkey delayed matching-to-sample, rat social recognition, and mouse inhibitory avoidance models that capture domains of working memory, short-term recognition memory, and long-term memory consolidation, respectively. Their results demonstrate that alpha-7 nAChR agonism can lead to broad-spectrum efficacy in animal models at doses that enhance ERK1/2 (extracellular-signal regulated kinase) and CREB (cAMP response element-binding protein) phosphorylation/activation and may represent a mechanism that offers potential to improve cognitive deficits associated with neurodegenerative and psychiatric diseases, such as Alzheimer's disease and schizophrenia.
The figure shows the general structure of this class of molecules. A-582941 enhanced cognitive performance in behavioral assays including the monkey delayed matching-to-sample, rat social recognition, and mouse inhibitory avoidance models that capture domains of working memory, short-term recognition memory, and long-term memory consolidation, respectively. Their results demonstrate that alpha-7 nAChR agonism can lead to broad-spectrum efficacy in animal models at doses that enhance ERK1/2 (extracellular-signal regulated kinase) and CREB (cAMP response element-binding protein) phosphorylation/activation and may represent a mechanism that offers potential to improve cognitive deficits associated with neurodegenerative and psychiatric diseases, such as Alzheimer's disease and schizophrenia.
Subscribe to:
Post Comments (Atom)
I wonder what effects it would have on the "normal" functioning brain. Perhaps a future smart drug?
ReplyDelete